Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 95%
filed 2026-06-12
The filing discloses results of two stockholder votes held on June 10, 2026: (1) an annual meeting where stockholders re-elected two directors and approved executive compensation and auditor ratification, and (2) a special meeting where stockholders approved an Investment Advisory Agreement for the Company's transition from internally managed to externally managed structure. The externalization represents a material structural change to the Company's operations, making these vote results material to investors.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-12
EX-99.1
The exhibit announces results of an extraordinary general meeting held on June 12, 2026, where shareholders approved two key resolutions: (1) a 35-for-1 share consolidation affecting both Class A and Class B ordinary shares, and (2) amendment and adoption of new memorandum and articles of association to reflect the consolidation. This is a direct disclosure of shareholder vote results on material corporate actions, matching the shareholder_vote_results taxonomy entry.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-12
Item 1.01
XCF Global entered into securities purchase agreements to issue 4,000,000 unregistered shares of Class A common stock for $600,000 in gross proceeds ($0.15/share) to accredited investors under Section 4(a)(2) and Regulation D Rule 506(b), with placement agent compensation of 7% cash fee (233,333 shares) plus 3% warrant coverage, creating material dilution to existing shareholders.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-12
EX-99.1
The exhibit announces that Cuprina has regained compliance with Nasdaq's minimum bid price requirement after receiving a Staff Delisting Determinations Letter on May 29, 2026, indicating the company's stock had closed below $1.00 for 30 consecutive business days. Although the announcement is positive (regaining compliance), the core disclosure is the resolution of a delisting risk event — the company was previously non-compliant and faced a scheduled hearing before the Nasdaq Hearing Panel on July 7, 2026, which has now been cancelled due to restored compliance. This is a material event affecting the registrant's continued listing status.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-12
Eva Live Inc. announced on June 12, 2026, that it "has reached terms for a definitive agreement under which EVA will hold a 51% ownership interest across Spiro Senior Living and related operating entities." This constitutes a material acquisition or change of control transaction—the company is acquiring majority ownership in an operating business. The disclosure of a definitive agreement for a 51% stake in operating entities is a classic M&A event material to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-12
Item 5.02
The filing discloses results of an annual stockholder meeting held on June 9, 2026, with detailed voting outcomes on five proposals: election of five directors (Nicolas Cary, Tucker Highfield, Evan Sohn, Manuel Stotz, and Kevin Wilson), ratification of Grassi & Co. as independent auditor, advisory vote on named executive officer compensation, approval of the 2026 Equity Incentive Plan, and approval of an amendment to the 2019 Plan to increase available shares. This is a classic Item 5.07 shareholder vote results disclosure with complete voting tallies and quorum information (74.91% voting power represented).
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-12
The filing discloses entry into a material definitive purchase agreement on June 10, 2026, whereby Aspire Biopharma agreed to acquire equity interests and assets of automotive systems businesses from FireFish TopCo, LLC for a purchase price of $30,000,000 plus adjustments. This is a material acquisition transaction disclosed under Item 1.01 (Entry into a Material Definitive Agreement), representing a significant business combination that would materially affect the registrant's operations and financial position.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-06-12
The 6-K discloses entry into Amendment No. 1 to an at-the-market (ATM) sales agreement dated June 11, 2026, which increases the aggregate offering price from $20 million to $60 million—a $40 million increase in authorized equity issuance. This is a material unregistered equity offering under Rule 415, with $9.3 million already sold as of April 1, 2026. The dilutive nature and capital-raising purpose are explicit, making this a dilutive_issuance event material to investors assessing the registrant's capitalization.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-12
Nasdaq imposed a trading halt under Code T12 on June 8, 2026, triggering the board to establish a special committee of independent directors to investigate unusual trading activities. While the company states it is unaware of material undisclosed developments, the trading halt itself and the formal investigation response constitute a material event affecting investor confidence and trading ability. This does not fit neatly into delisting_risk (no notice of delisting), but represents a significant trading disruption warranting disclosure.
View raw filing on EDGAR →
6-K
Governance Other
confidence 70%
filed 2026-06-12
EX-99.1
Knorex held an Extraordinary General Meeting on 24 June 2026 to vote on the removal of director Wilson Chandra and the appointment of three new directors: Kai Zhong, Lu Liu, and Truong Vinh Phu Le. The meeting notice and proxy card disclose material changes to board composition.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-12
Arrive AI Inc. entered into an Equity Distribution Agreement with Maxim Group LLC on June 11, 2026, to sell up to $14,967,247 of common stock through an "at the market offering" program. This is a classic dilutive equity issuance under Item 1.01, where the company is authorized to raise capital by selling shares at market prices, with Maxim acting as sales agent at a 2.5% commission. The material amount and equity dilution to existing shareholders make this a reportable material event.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-06-12
Mr. Chay Weei Jye resigned from his position as Co-Chief Executive Officer and as a director of Black Titan Corporation, effective June 12, 2026. The departure of a named executive officer at the C-suite level is a material event that would affect a reasonable investor's assessment of the registrant's leadership and governance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-12
The filing discloses a registered direct offering of 311,876 common shares and a concurrent private placement of 311,876 warrants (exercisable at $4.008 per share for 5 years) for aggregate gross proceeds of approximately $1.25 million. Item 1.01 describes entry into a securities purchase agreement, and Item 3.02 explicitly addresses unregistered sales of equity securities. This is a classic dilutive equity issuance combining registered and unregistered securities, material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →
6-K
Periodic Interim
confidence 95%
filed 2026-06-12
This 6-K furnishes unaudited condensed consolidated financial statements for the six-month period ended January 31, 2026, together with management's discussion and analysis. The filing explicitly states "On June 12, 2026 the Company announced its unaudited consolidated financial results for the six month period ended January 31, 2026." This is a periodic interim financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings press release. The document includes full financial statements (balance sheet, statements of operations, changes in equity, and cash flows) with accompanying notes, which is characteristic of a periodic filing rather than an event disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-12
Item 2.02
The filing discloses quarterly financial results for the period ended April 30, 2026 via a press release furnished as Exhibit 99.1 under Item 2.02. This is a standard earnings release disclosure, which is material to investors as it provides periodic financial performance information essential to assessing the registrant's operating results and financial condition.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-12
Item 8.01
The filing discloses a special meeting of stockholders held on June 11, 2026, to vote on a merger and spinoff transaction involving Jet.AI, SpinCo, flyExclusive, and FlyX Merger Sub. The core event is the adjournment of the special meeting to June 23, 2026, due to failure to achieve the required majority vote (only 34.2% of shares represented, with ~99% voting in favor but needing majority of all outstanding shares). This is a material acquisition/reorganization activity under Items 1.01 and 2.01, as the transaction involves a merger agreement and spinoff agreement that would result in a change of control and distribution of SpinCo shares to flyExclusive shareholders.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-12
Item 3.01 discloses that OFA Group received notice from Nasdaq on June 9, 2026, that it has failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The company has been granted a second 180-day compliance period (until December 7, 2026) to regain compliance, with explicit warning that failure to do so will result in delisting notification and potential loss of Nasdaq listing. This is a material delisting risk event requiring disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-12
The filing discloses results of an annual stockholder meeting held June 12, 2026, with voting outcomes on five proposals: election of directors (Keith A. Goldan and Bernhardt G. Zeiher, M.D.), advisory vote on named executive officer compensation, ratification of Deloitte & Touche LLP as auditor, approval of increased equity plan shares (8.4M to 11.5M), and a failed amendment to remove advance notice provisions for director nominations. This is a classic Item 5.07 shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-12
Item 3.01
The filing discloses a Nasdaq deficiency notice under Item 3.01 regarding failure to satisfy the stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)). The Company reported negative stockholders' equity of $(12,447,801) as of December 31, 2025, well below the $2,500,000 minimum. While Nasdaq granted an extension through October 12, 2026, the Company faces delisting if it fails to evidence compliance by that deadline or upon filing its 2026 periodic report. This is a material delisting risk event.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-12
Matthew Faber resigned from Tri-County Financial Group's Board of Directors, effective June 11, 2026. The filing discloses a director departure under Item 5.02, with explicit confirmation that the resignation was not due to disagreement with the Company. Board departures are material events affecting the composition of the registrant's governance structure.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-12
The filing discloses announcement of initial cash dividends on the Company's 9.50% Series A Perpetual Preferred Stock via press release under Item 7.01 (Regulation FD Disclosure). While dividend announcements are routine for mature companies, the initiation of dividends on preferred stock—particularly at a 9.50% rate—signals capital structure changes and cash distribution policy that would be material to investors assessing the registrant's financial position and capital allocation strategy. However, the lack of detail in the 8-K body itself (the actual press release is attached as an exhibit) and the use of Item 7.01 (rather than a more specific Item) creates some ambiguity about whether this is a routine preferred dividend announcement or a more significant capital event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-12
The filing discloses results of an annual stockholder meeting held on June 11, 2026, under Item 5.07. The company reports voting outcomes for three matters: election of six directors (with detailed vote tallies for each nominee), ratification of Eide Bailly LLP as independent auditor, and approval of a certificate amendment to increase authorized common shares to 35,000,000. All three proposals passed with substantial majorities, making this a standard shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-12
The filing discloses Item 3.01 regarding a Nasdaq compliance notice dated June 12, 2026. While the notice confirms the Company has now achieved compliance with Listing Rule 5250(c)(1) (periodic filing requirement) and closes a prior non-compliance matter from May 21, 2026, the disclosure itself documents a delisting risk event—the Company had previously failed to satisfy a continued listing standard and received a notice of non-compliance. The resolution of this matter is material to investors as it addresses a direct threat to the Company's continued listing on Nasdaq.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
The filing discloses results of Neuraxis, Inc.'s annual meeting of stockholders held on June 10, 2026, under Item 5.07. It reports voting outcomes for four matters: election of six directors (all approved with >96% support), ratification of auditor Rosenberg Rich Baker Berman, P.A., amendment to the 2022 Omnibus Securities and Incentive Plan, and approval of the 2025 Employee Stock Purchase Plan. These are routine but material shareholder governance matters.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-12
The filing discloses Board approval of the 2026 Equity Incentive Plan and grants of stock options to named executive officers (Carlos X. Montoya, Ken Park, Brad Hoffman, John Jubilee, and Patrick White) and other employees/service providers. The disclosure details vesting schedules, performance conditions, and exercise prices for equity awards, which constitutes a compensatory arrangement under Item 5.02(e). This is material as it affects executive compensation structure and potential dilution to shareholders.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-12
The filing's primary disclosure is Item 3.01, which reports MicroVision's application to transfer listing from The Nasdaq Global Market to The Nasdaq Capital Market due to failure to maintain the $1.00 minimum bid price requirement. The company previously received a deficiency notice in January 2026 and now seeks a transfer to avoid delisting, with an additional 180-calendar-day grace period to regain compliance. This is a material delisting-risk event that would significantly affect investor assessment of the company's exchange status and trading continuity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-12
Venu Holding Corporation entered into an ATM (at-the-market) Sales Agreement with ThinkEquity LLC on June 12, 2026, authorizing the sale of up to $250 million in common stock shares. This is a dilutive equity issuance disclosed under Item 1.01 (Entry into a Material Definitive Agreement). ATM offerings are a classic signal of capital raising at small- and mid-cap issuers and would materially affect investor assessment of share dilution and the company's financing strategy.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-12
Celularity received written notice from Nasdaq on June 9, 2026, that its Market Value of Listed Securities fell below the $35 million minimum required under Nasdaq Listing Rule 5550(b)(2). The company has been granted a 180-day compliance period (until December 7, 2026) to regain compliance, with explicit warning that failure to do so will result in delisting notification. This is a classic delisting risk disclosure under Item 3.01, material to any investor assessing the company's continued public market access.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-12
Item 3.01 discloses that NYSE American's Regulatory Staff determined Perfect Moment Ltd. failed to regain compliance with minimum stockholders' equity requirements by the end of the 18-month compliance period and is "no longer suitable for continued listing." The company's common stock will be suspended from NYSE American during the week of June 15, 2026, and transition to OTC Markets trading. This is a material delisting event that fundamentally affects the registrant's market access and liquidity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-12
Item 2.01
Item 3.02 explicitly discloses an unregistered sale of equity securities (the "Company Shares") issued to Founding Shareholders in a transaction exempt from registration under Section 4(a)(2) and/or Regulation D. The shares are restricted securities under Rule 144. The reference to a Stock Purchase Agreement and the closing of a Purchase Agreement indicates a material equity issuance that would dilute existing shareholders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
The 8-K discloses results of AST SpaceMobile's Annual Meeting held on June 12, 2026, under Item 5.07. The filing reports voting outcomes on three proposals: (i) election of 10 directors, (ii) ratification of KPMG LLP as independent auditor, and (iii) advisory vote on named executive officer compensation. All three proposals passed with substantial majorities, and the detailed vote tallies are provided for each director and proposal.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-12
The filing discloses a securities purchase agreement with 1800 Diagonal Lending for a convertible promissory note with an original issue discount and conversion rights at 61% of the lowest closing bid price over ten trading days, with potential conversion of up to 19.99% of outstanding shares. Item 3.02 explicitly addresses unregistered sales of equity securities under Section 4(a)(2) and Regulation D, and the conversion feature creates significant dilution risk to existing shareholders. This is a classic PIPE-like structure typical of distressed financing at small-cap issuers.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-12
Item 1.01
Ocean Capital Acquisition Corp consummated its IPO on June 10, 2026, raising $115 million in gross proceeds ($100 million from the initial offering plus $15 million from the over-allotment option) through entry into material definitive agreements including the Underwriting Agreement, Warrant Agreement, Rights Agreement, Investment Management Trust Agreement, and Sponsor Private Placement Units Purchase Agreement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-12
Item 3.02
The company completed an unregistered private placement of 150,000 units to the Sponsor at $10.00 per unit ($1.5 million aggregate) pursuant to Section 4(a)(2) exemption, simultaneously with the IPO closing.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-12
Item 5.02
Three directors—Pok Yu Chow, Hiu Man Cheng, and Hin Wing Wong—were appointed to the Board on May 4, 2026 in connection with the IPO and subsequently appointed to the Audit and Compensation Committees effective June 10, 2026, establishing the governance structure of the newly public company.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-06-12
Item 5.02
William Conkling, Executive Vice President and Chief Financial Officer, resigned effective June 15, 2026. The company disclosed his departure via press release on June 12, 2026, and entered into a separation agreement with consulting fee arrangements.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a clear Item 5.07 disclosure of shareholder voting results from Warby Parker's June 8, 2026 Annual Meeting of Stockholders. The filing reports voting outcomes for three proposals: election of three Class II directors (Dave Gilboa, Youngme Moon, and Ronald Williams), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition and corporate oversight.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-06-12
Item 5.03
Wheeler Real Estate Investment Trust, Inc. implemented a one-for-four reverse stock split effective June 17, 2026, via amendments to the Company's charter filed with Maryland. This material modification to the rights of security holders affects share structure, trading mechanics, and conversion terms for convertible securities and preferred stock.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-12
Item 3.02
Avalo Therapeutics exchanged 4,294.675 shares of Series C Preferred Stock for newly created Series C-1 Preferred Stock in an unregistered transaction with an accredited investor, removing the 4.99% beneficial ownership restriction and allowing the investor to increase ownership to 9.99%. The Series C-1 Preferred Stock includes conversion rights (1,000 shares of Common Stock per preferred share), broad-based weighted average anti-dilution protection, and dividend parity, materially affecting shareholder concentration and dilution risk.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-12
Item 5.02
Avalo Therapeutics amended employment agreements for four named executives (CEO Dr. Neil, CFO Sullivan, CMO Dr. Doyle, and CBO Boyd) to modify severance, change-of-control payments, equity acceleration, and 280G tax gross-up provisions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-12
Item 1.01
This Item 1.01 discloses the entry into a material definitive agreement—the Pooling and Servicing Agreement dated May 1, 2026, which established BBCMS Mortgage Trust 2026-5C41 and caused the issuance of commercial mortgage pass-through certificates backed by 33 mortgage loans. The filing also describes a subsequent servicing arrangement change for one loan (The Towers at Cupertino City Center) transferred to a separate BANK 2026-5YR22 securitization as of June 11, 2026. These are material securitization and servicing transactions that would affect investor assessment of the trust's structure and asset composition.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-06-12
Trinity Biotech entered into an At the Market Offering Agreement with Lucid Capital Markets on June 12, 2026, authorizing the sale of up to $4,352,314 of American Depositary Shares (ADSs). This is a dilutive equity issuance under an ATM program, which allows the company to raise capital through the sale of registered securities at market prices. The filing discloses the material terms, including the 3.0% commission to the sales agent and the underlying registration statement (Form F-3 File No. 333-280391).
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-12
Item 4.01
The filing discloses a change in the registrant's independent registered public accounting firm: Ernst & Young LLP (EY) will be dismissed effective upon completion of the audit for fiscal year ending June 30, 2027, and Deloitte & Touche LLP has been selected as the new auditor for fiscal year ending June 30, 2028. This is a classic auditor change under Item 4.01, with no adverse circumstances (no disagreements, no reportable events, and no qualified audit opinions noted).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Evolus's Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting outcomes for three proposals: election of Class II directors (Brady Stewart and Vikram Malik), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with majority support, and the detailed vote tallies (For/Against/Abstain/Broker Non-Vote) are the core content of the disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of TheRealReal's June 10, 2026 annual meeting of stockholders. The filing presents voting outcomes for six proposals: election of Class I directors (Caretha Coleman, Karen Katz, Mark McCaffrey), ratification of KPMG LLP as auditor, advisory vote on named executive officer compensation, and three failed management proposals to amend the Certificate of Incorporation. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) are the hallmark of shareholder vote result disclosures required under Item 5.07.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-12
Item 7.01
The filing discloses conclusion of a "strategic review process" via press release on June 12, 2026, but the Item 7.01 disclosure provides no substantive detail about the outcome, recommendations, or implications. Without access to Exhibit 99.1, the specific nature of the strategic review conclusion cannot be determined—it could relate to M&A activity, asset sales, operational restructuring, or other material corporate actions. The materiality and event classification depend critically on the press release content, which is referenced but not excerpted in the Item itself.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-12
Item 1.01
The filing discloses Amendment No. 2 to a warrant originally issued under a Securities Purchase Agreement dated March 17, 2026. The amendment reduces the exercise price from $16.00 to $3.00 per share for a 90-day period, substantially increasing the likelihood and incentive for exercise. This modification materially enhances the dilutive potential of the warrant and would affect a reasonable investor's assessment of share dilution and capital structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-12
Item 1.01
OUTFRONT Media entered into a material definitive agreement on June 12, 2026, to issue $500 million in 6.000% Senior Notes due 2034. This debt issuance represents a material capital structure event with detailed covenant restrictions and default provisions that significantly affect the company's financial position and obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This Item 5.07 disclosure reports the results of Summit Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026, with detailed voting tabulations for four proposals: election of nine directors, ratification of PricewaterhouseCoopers LLP as auditor, non-binding advisory vote on named executive officer compensation, and approval of a stock incentive plan amendment to increase shares by 8,000,000. All proposals were approved by the requisite stockholder vote, making this a clear shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a clear disclosure of shareholder voting results from ZipRecruiter's June 9, 2026 Annual Meeting of Stockholders under Item 5.07. The filing reports final voting tallies on three proposals: election of directors (Brie Carere and Mike Gupta), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition and corporate oversight.
View raw filing on EDGAR →